Anti-TROP-2 Antibody-drug Conjugate OBI-902

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), site-specifically conjugated to the cytotoxic agent and DNA topoisomerase I inhibitor exatecan via a glycan linker, with potential antineoplastic activity. Upon administration of anti-TROP-2 ADC OBI-902, the anti-TROP-2 antibody moiety targets and binds to TROP-2 expressed on tumor cells. Upon binding and internalization, exatecan is released, binds to topoisomerase-1 and inhibits topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.

**Synonyms:** - Anti-TROP-2 ADC OBI-902 - Anti-TROP-2/Exatecan ADC OBI-902 - Anti-TROP2 Antibody-drug Conjugate OBI-902 - OBI 902 - OBI-902 - OBI902